Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves.
Journal
JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
7
7
2021
medline:
22
12
2021
entrez:
6
7
2021
Statut:
ppublish
Résumé
COVID-19 cancer patients (C19-CP) represent a population at high risk for mortality, whose clinical characteristics are still unknown in the second SARS-CoV-2 wave. The aim of this retrospective study was to compare epidemiology and clinical presentation of C19-CP referring to the emergency department (ED) of our institution (San Luigi Gonzaga University Hospital, Orbassano, Turin, Italy), in a 3-week observation period of the first and second COVID-19 waves, starting from the introduction of the corresponding national lockdowns. We retrieved ED admissions from March 9 to 29, 2020, for the first wave, and from October 24 to November 13, 2020, for the second wave. We collected clinical characteristics of consecutive patients with molecularly confirmed SARS-CoV-2 infection. We also considered untested or SARS-CoV-2-negative cancer patients referring to the ED in the reference time frames. C19-CP in the second wave exceeded those in the first wave despite the nonsignificant difference (39 of 576 C19-CP were a vulnerable population, irrespective of the COVID-19 waves. This highlights the need to prioritize vaccinations in oncological patients to safeguard and guarantee optimal anticancer care.
Identifiants
pubmed: 34228511
doi: 10.1200/OP.21.00098
pmc: PMC8677967
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1887-e1894Références
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Int J Infect Dis. 2020 Sep;98:188-190
pubmed: 32574692
Front Oncol. 2020 Aug 19;10:1722
pubmed: 32974210
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Appl Health Econ Health Policy. 2020 Aug;18(4):509-517
pubmed: 32495067